LBA54ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC)
Motzer, R J, Lee, C-H, Emamekhoo, H, Matrana, M, Percent, I, Hsieh, J J, Hussain, A, Vaishampayan, U N, Graham, R, Liu, S, McCune, S, Shaheen, M, Parmar, H, Shen, Y, Whiting, S H, Tannir, N MVolume:
30
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz394.048
Date:
October, 2019
File:
PDF, 88 KB
english, 2019
File converter
More search results
More benefits 
